Effects of canagliflozin on human myocardial redox signalling: clinical implications.

Published on Jul 19, 2021in European Heart Journal29.983
· DOI :10.1093/EURHEARTJ/EHAB420
Murray D. Polkinghorne3
Estimated H-index: 3
(John Radcliffe Hospital)
Aims null Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects, on myocardial redox signalling in humans. null Methods and results null Study 1 included 364 patients undergoing cardiac surgery. Right atrial appendage biopsies were harvested to quantify superoxide (O2.-) sources and the expression of inflammation, fibrosis, and myocardial stretch genes. In Study 2, atrial tissue from 51 patients was used ex vivo to study the direct effects of canagliflozin on NADPH oxidase activity and nitric oxide synthase (NOS) uncoupling. Differentiated H9C2 and primary human cardiomyocytes (hCM) were used to further characterize the underlying mechanisms (Study 3). SGLT1 was abundantly expressed in human atrial tissue and hCM, contrary to SGLT2. Myocardial SGLT1 expression was positively associated with O2.- production and pro-fibrotic, pro-inflammatory, and wall stretch gene expression. Canagliflozin reduced NADPH oxidase activity via AMP kinase (AMPK)/Rac1signalling and improved NOS coupling via increased tetrahydrobiopterin bioavailability ex vivo and in vitro. These were attenuated by knocking down SGLT1 in hCM. Canagliflozin had striking ex vivo transcriptomic effects on myocardial redox signalling, suppressing apoptotic and inflammatory pathways in hCM. null Conclusions null We demonstrate for the first time that canagliflozin suppresses myocardial NADPH oxidase activity and improves NOS coupling via SGLT1/AMPK/Rac1 signalling, leading to global anti-inflammatory and anti-apoptotic effects in the human myocardium. These findings reveal a novel mechanism contributing to the beneficial cardiac effects of canagliflozin.
📖 Papers frequently viewed together
#1Detmar Kolijn (RUB: Ruhr University Bochum)H-Index: 4
#2Steffen Pabel (University of Regensburg)H-Index: 4
Last. Inês Falcão-Pires (University of Porto)H-Index: 24
view all 22 authors...
AIMS: Sodium-glucose-cotransporter-2 (SGLT2) inhibitors showed favourable cardiovascular outcomes, but the underlying mechanisms are still elusive. This study investigated the mechanisms of empagliflozin in human and murine heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: The acute mechanisms of empagliflozin were investigated in human myocardium from patients with HFpEF and murine ZDF obese rats, which were treated in vivo. As shown with immunoblots and ELISA, empagl...
#1John J.V. McMurray (Glas.: University of Glasgow)H-Index: 202
#2Scott D. Solomon (Brigham and Women's Hospital)H-Index: 158
Last. Jan Bělohlávek (Charles University in Prague)H-Index: 12
view all 38 authors...
Abstract Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-ind...
#1Ioannis Akoumianakis (University of Oxford)H-Index: 11
#2Fabio Sanna (University of Oxford)H-Index: 7
Last. Evangelos Oikonomou (University of Oxford)H-Index: 32
view all 27 authors...
Obesity is associated with changes in the secretome of adipose tissue (AT), which affects the vasculature through endocrine and paracrine mechanisms. Wingless-related integration site 5A (WNT5A) and secreted frizzled-related protein 5 (SFRP5), adipokines that regulate noncanonical Wnt signaling, are dysregulated in obesity. We hypothesized that WNT5A released from AT exerts endocrine and paracrine effects on the arterial wall through noncanonical RAC1-mediated Wnt signaling. In a cohort of 1004 ...
#1John J.V. McMurray (Glas.: University of Glasgow)H-Index: 202
#2David L. DeMets (UW: University of Wisconsin-Madison)H-Index: 87
Last. Scott D. Solomon (Brigham and Women's Hospital)H-Index: 158
view all 12 authors...
The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes, pre-diabetes and a normal glycated haemoglobin (HbA1c) in DAPA-HF. Adults with HF in New York Heart Association functional class ≥ II, a left ventric...
#5Fei Han (Tianjin Medical University)H-Index: 6
Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an insulin-independent manner. The aim of this study was to investigate the effect of empagliflozin on myocardium injury and the potential mechanism in type 2 diabetic KK-Ay mice. Thirty diabetic KK-Ay mice were administered...
Abstract Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. Methods We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocar...
#1Sara B. Seidelmann (Harvard University)H-Index: 16
#2Elena V. Feofanova (University of Texas Health Science Center at Houston)H-Index: 8
Last. Scott D. Solomon (Harvard University)H-Index: 158
view all 17 authors...
Abstract Background Loss-of-function mutations in the SGLT1 (sodium/glucose co-transporter-1) gene result in a rare glucose/galactose malabsorption disorder and neonatal death if untreated. In the general population, variants related to intestinal glucose absorption remain uncharacterized. Objectives The goal of this study was to identify functional SGLT1 gene variants and characterize their clinical consequences. Methods Whole exome sequencing was performed in the ARIC (Atherosclerosis Risk in ...
#1Kwong-Man Ng (Li Ka Shing Faculty of Medicine, University of Hong Kong)H-Index: 5
#2Yee-Man Lau (Li Ka Shing Faculty of Medicine, University of Hong Kong)H-Index: 9
Last. Chung-Wah Siu (Li Ka Shing Faculty of Medicine, University of Hong Kong)H-Index: 7
view all 8 authors...
Empagliflozin, a sodium-glucose co-transporter (SGLT) inhibitor, reduces heart failure and sudden cardiac death but the underlying mechanisms remain elusive. In cardiomyocytes, SGLT1 and SGLT2 expression is upregulated in diabetes mellitus, heart failure, and myocardial infarction. We hypothesise that empagliflozin exerts direct effects on cardiomyocytes that attenuate diabetic cardiomyopathy. To test this hypothesis, cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) were...
#1Bryan WilliamsH-Index: 8
#2G. ManciaH-Index: 22
Last. A DominiczakH-Index: 3
view all 28 authors...
#1Stefan D. Anker (Charité)H-Index: 113
#2Javed Butler (University of Mississippi)H-Index: 74
Cited By2
#1Mi Seon Seo (Kangwon National University)H-Index: 6
#2Jin Ryeol An (Kangwon National University)H-Index: 5
Last. Won Sun Park (Kangwon National University)H-Index: 21
view all 9 authors...
Abstract null null Aims null Canagliflozin is an anti-diabetic agent and sodium glucose co-transporter-2 inhibitor. Despite numerous clinical trials demonstrating its beneficial effects on blood pressure, the cellular mechanisms underlying the effects of canagliflozin on vascular reactivity have yet to be clarified. We investigated the vasodilatory effect of canagliflozin on aortic rings isolated from rabbits. null null null Main methods null We used rabbit thoracic aortic rings and its arterial...
Selective sodium–glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalization for heart failure in patients with or without type 2 diabetes (T2DM) in large-scale clinical trials. The exact mechanism of action is currently unclear. The dual SGLT1/2 inhibitor sotagliflozin not only reduced hospitalization for HF in patients with T2DM, but also lowered the risk of myocardial infarction and stroke, suggesting a possible additional benefit related to SGLT1 inhibition. In fact, sever...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.